SHCHealthcare · Diagnostics & ResearchThe 10 Wall Street analysts covering Sotera Health Co. hold a median 12-month price target of $23 — +15.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Sotera Health Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (90): The business earns solid, repeatable profits on what it owns.
Accruals (54): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (23): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +15.0% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Barclays | Maintains | Overweight | $19 → $22 |
| 7 Aug 2026 | Citigroup | Maintains | Buy | $23 → $25 |
| 7 Aug 2026 | JP Morgan | Maintains | Neutral | $16 → $18 |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | $22 → $25 |
| 24 June 2026 | Barclays | Maintains | Overweight | — |
| 24 June 2026 | Barclays | Maintains | Overweight | $18 → $19 |
| 5 June 2026 | Goldman Sachs | Initiates | Buy | — |
| 6 May 2026 | Piper Sandler | Reiterates | Overweight | — |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
| 24 Feb 2026 | Citigroup | Maintains | Buy | — |
| 9 Jan 2026 | Piper Sandler | Upgrade | Overweight | — |
| 9 Jan 2026 | RBC Capital | Reinstates | Outperform | $24 |
| 18 Dec 2025 | William Blair | Initiates | Outperform | — |
| 13 Nov 2025 | BMO Capital | Initiates | Outperform | — |
| 5 Nov 2025 | Barclays | Maintains | Overweight | — |
| 5 Nov 2025 | JP Morgan | Maintains | Neutral | — |
| 5 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 2 Oct 2025 | Barclays | Maintains | Overweight | — |
| 24 June 2025 | Barclays | Maintains | Overweight | — |
| 5 May 2025 | Goldman Sachs | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SHC appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 24% of US stocks
Cheaper than 28% of US stocks
Cheaper than 13% of US stocks
Cheaper than 29% of US stocks
Higher than 50% of US stocks
Higher than 96% of US stocks
Higher than 69% of US stocks
Higher than 91% of US stocks
Higher than 75% of US stocks
Higher than 87% of US stocks
Higher than 90% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Sotera Health Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Sotera Health reported second-quarter 2026 results featuring 8% constant-currency revenue growth, higher adjusted EBITDA margins, and an upward revision to its full-year revenue and adjusted EBITDA outlook, as detailed in its Q2 earnings call.
Why it matters — Sotera Health watchers would note that the company raised its full-year revenue and adjusted EBITDA guidance while reporting improved margins and revenue growth.
Seeking Alpha published the transcript of Sotera Health Company's Q2 2026 earnings call, which covers the company's second-quarter 2026 financial results and management commentary.
Why it matters — A SHC watcher would care because the transcript offers direct insight into how management discussed the company's quarterly performance and its forward-looking outlook.
Zacks reports on Sotera Health's (SHC) Q2 earnings for the quarter ended June 2026, examining how its revenue and EPS compare with Wall Street estimates and year-ago figures. The piece focuses on key metrics versus analyst expectations rather than detailing actual numerical results.
Why it matters — SHC watchers would care because the comparison of Q2 metrics against Wall Street estimates indicates whether the company met analyst expectations for the quarter.
Sotera Health Company reported Q2 quarterly earnings of $0.26 per share, surpassing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.20 per share in the same quarter a year ago.
Why it matters — A SHC watcher would note that the company exceeded analyst earnings expectations for the quarter, while also improving on its year-ago performance.
Sotera Health reported second-quarter 2026 net revenues up 9.2% (8.0% on a constant currency basis) year over year, with net income of $54 million versus $8 million in Q2 2025. The company raised its full-year 2026 outlook for net revenue growth to 5.25%-6.75% and Adjusted EBITDA growth to 5.75%-7.25% on a constant currency basis.
Why it matters — A watcher would care because the stronger-than-expected results and raised full-year guidance signal sustained momentum across the company's business units.
The 10 Wall Street analysts covering Sotera Health Co. have a median 12-month price target of $23, with estimates ranging from $18 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Sotera Health Co., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sotera Health Co. 96 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Sotera Health Co. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (90 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +15.0% from the last close, and Ticker Nerd's factor model ranks Sotera Health Co. 96 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Sotera Health Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $25 over the next 12 months.
Sotera Health Co. returned +22.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Sotera Health Company is a leading provider of mission-critical health and sterilization services. It plays a vital role in ensuring safety and compliance across medical device, pharmaceutical, food, and other industries that require stringent sterilization and laboratory testing services.
The most recent item we track (MarketBeat, 7 Aug 2026): "Sotera Health Q2 Earnings Call Highlights". Sotera Health reported second-quarter 2026 results featuring 8% constant-currency revenue growth, higher adjusted EBITDA margins, and an upward revision to its full-year revenue and adjusted EBITDA outlook, as detailed in its Q2 earnings call.
Sotera Health Company is a leading provider of mission-critical health and sterilization services. It plays a vital role in ensuring safety and compliance across medical device, pharmaceutical, food, and other industries that require stringent sterilization and laboratory testing services. The company operates under three key business units: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides end-to-end sterilization solutions using innovative technologies to eliminate pathogens from medical and other consumable products. Nordion is instrumental in supplying Cobalt-60 that facilitates the radiation sterilization process, essential for medical devices, pharmaceuticals, and food safety industries. Nelson Labs delivers comprehensive testing and consultancy services, supporting organizations in gaining and maintaining regulatory approvals. Sotera Health's integrated solutions are crucial for maintaining public health standards and meeting regulatory compliance, making it an indispensable entity in the global health landscape. As an established operator with a broad international presence, Sotera Health Company underscores the importance of safety and reliability in its service offerings, significantly impacting industries reliant on rigorous safety standards.
CEO Mr. Alton E. Shader · 3,000 employees · United States · https://soterahealth.com